The World Health Organization (WHO) has announced it has once again suspended recruitment of the hydroxychloroquine arm of its Covid-19 Solidarity trial.
According to a release, the principal investigators of the trial made this decision because of the results of the Solidarity Trial, the UK’s RECOVERY trial and a Cochrane review of other evidence.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“Data from Solidarity (including the French Discovery trial data) and the recently announced results from the UK’s RCECOVERY trial both showed that hydroxychloroquine does not result in the reduction of mortality of hospitalised COVID-19 patients, when compared with standard of care.”
This decision within two weeks of the WHO announcing it was re-starting the recruitment of the hydroxychloroquine arm of Solidarity trial.
